DR. FREDERICK KING GOODWIN, M.D.
Psychiatric at Warwick Pl, Bethesda, MD
License number
Maryland D000 2195
Category
Psychiatric
Type
Psychiatry
Address
Address
5712 Warwick Pl, Bethesda, MD 20815
Phone
(301) 951-0405
(301) 951-0813 (Fax)
(301) 951-0813 (Fax)
Personal information
See more information about FREDERICK KING GOODWIN at radaris.comName
Address
Phone
5712 Warwick Pl, Chevy Chase, MD 20815
6069 Ivy League Dr, Catonsville, MD 21228
829 Holly Dr E, Annapolis, MD 21409
16817 Malabar St, Derwood, MD 20855
2613 Mckenzie Rd, Ellicott City, MD 21042
Professional information
Method Of Treating Psoriasis Using Synthetic Peptide Compositions
US Patent:
5248667, Sep 28, 1993
Filed:
Jul 18, 1991
Appl. No.:
7/732352
Inventors:
Peter Bridge - Washington DC
Frederick K. Goodwin - Chevy Chase MD
Frederick K. Goodwin - Chevy Chase MD
Assignee:
The United States of America as represented by the Secretary of the
Department of Health & Human Services - Washington DC
Department of Health & Human Services - Washington DC
International Classification:
A61K 3702, C07K 706
US Classification:
514 15
Abstract:
Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in patients who lack antibodies against HIV.
Dr. Frederick K Goodwin, Chevy Chase MD - MD (Doctor of Medicine)
Specialties:
Psychiatry, Clinical Pharmacology
Address:
Frederick K Goodwin MD
5712 Warwick Pl, Chevy Chase 20815
(301) 294-6899 (Phone)
5712 Warwick Pl, Chevy Chase 20815
(301) 294-6899 (Phone)
Languages:
English
Education:
Medical School
Saint Louis University / School of Medicine
Graduated: 1963
University Hospital SUNY Health Science Center
University Of Nc Hosps
Saint Louis University / School of Medicine
Graduated: 1963
University Hospital SUNY Health Science Center
University Of Nc Hosps
Composition For The Treatment Of Chronic Fatigue Syndrome
US Patent:
5189022, Feb 23, 1993
Filed:
May 8, 1991
Appl. No.:
7/696556
Inventors:
Thomas P. Bridge - Washington DC
Frederick K. Goodwin - Chevy Chase MD
Frederick K. Goodwin - Chevy Chase MD
Assignee:
The United States of America as represented by the Secretary of Health
and Human Services - DC
and Human Services - DC
International Classification:
A61K 3702
US Classification:
514 16
Abstract:
The present invention relates to a method of treating chronic fatigue syndrome not associated with an HIV infection. In the method of the present invention patients are administered a pharmaceutically acceptable carrier together with
(1) a neuropsychiatrically effective amount of a linear peptide of formula (I):
R. sup. a -Ser-Thr-Thr-Thr-Asn-Tyr-R. sup. 6 (I)
wherein
R. sup. a is Ala, D-Ala or Cys-Ala-, and
R. sup. 6 is Thr, Thr-amide, Thr-Cys or Thr-Cys-amide,
or a derivative of the peptide or a physiologically acceptable salt thereof; or
(2) a neuropsychiatrically effective amount of a linear peptide of formula (II):
R. sup. 1 -R. sup. 2 -R. sup. 3 -R. sup. 4 -R. sup. 5 (II)
wherein
R. sup. 1 is X-Y or Y when Y is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu-, and X is Cys;
R. sup.
Compositions Having Use As Treatment Of Neuropsychiatric Deficits
US Patent:
5063206, Nov 5, 1991
Filed:
May 16, 1989
Appl. No.:
7/352313
Inventors:
Peter Bridge - Washington DC
Frederick K. Goodwin - Chevy Chase MD
Frederick K. Goodwin - Chevy Chase MD
Assignee:
The United States of Americas as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3702, C07K 708
US Classification:
514 16
Abstract:
The present invention relates to methods of treating mental disorders and memory deficits not caused by HIV infection. The methods involve administration of a thymoleptic effective amount of defined linear peptides to patients. The peptides can be administered for example, as a powder or a solution obtained by dissolving a powder in a pharmaceutically acceptable solvent.